{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:17:05Z","timestamp":1782962225229,"version":"3.54.5"},"reference-count":36,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The amyloidogenic V122I variant of the transthyretin (TTR) gene is found in \u223c3% of African American individuals and increases cardiovascular mortality risk after the age of 65 years. Sickle cell disease (SCD) primarily affects individuals of African descent, leading to multiorgan damage and premature mortality, with cardiopulmonary issues being a major cause of death. We assessed the impact of TTR V122I on cardiac phenotype and survival in a study of 584 patients with SCD (mean age, 35.9 years; 50.7% women). The prevalence was 3.1% (18\/584), mainly female (72.2%). Age, blood pressure, body mass index, and liver\/renal markers were similar between carriers and noncarriers, except for higher blood urea nitrogen levels in carriers. Echocardiography showed that carriers had increased septal thickness and left ventricular mass index and lower diastolic function indices. Over a median follow-up of 6.5 years, 219 patients died. The coinheritance of TTR V122I with SCD was associated with increased mortality (hazard ratio, 2.82; 95% confidence interval, 1.57-5.06). At 5 years, the cumulative incidence of death was 52.9% among carriers compared with 14.5% among noncarriers, corresponding to an approximate relative risk of 3.6. TTR protein levels were significantly lower in carriers. In conclusion, TTR V122I prevalence in patients with SCD mirrors that of the general African American population but affects cardiovascular function much earlier, and a contributing factor may be the underlying oxidative stress and chronic anemia. Genetic screening for TTR V122I is important and should be considered for patients with SCD. This trial was registered at www.clinicaltrials.gov as NCT00011648.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026019698","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:54:31Z","timestamp":1775069671000},"page":"4000-4008","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Transthyretin V122I variant and protein affect cardiac severity and mortality in sickle cell disease"],"prefix":"10.1182","volume":"10","author":[{"given":"Haiou","family":"Li","sequence":"first","affiliation":[{"name":"1Sickle Cell Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3009-3863","authenticated-orcid":false,"given":"Shijinqiu","family":"Gao","sequence":"additional","affiliation":[{"name":"1Sickle Cell Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunde","family":"Wang","sequence":"additional","affiliation":[{"name":"1Sickle Cell Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Asomaning","sequence":"additional","affiliation":[{"name":"1Sickle Cell Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Conrey","sequence":"additional","affiliation":[{"name":"1Sickle Cell Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britney","family":"Kruah","sequence":"additional","affiliation":[{"name":"1Sickle Cell Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6961-8122","authenticated-orcid":false,"given":"Jungnam","family":"Joo","sequence":"additional","affiliation":[{"name":"2Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin O.","family":"Wu","sequence":"additional","affiliation":[{"name":"2Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1168-5055","authenticated-orcid":false,"given":"Vandana","family":"Sachdev","sequence":"additional","affiliation":[{"name":"3Echocardiography Laboratory, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9835-6501","authenticated-orcid":false,"given":"Swee Lay","family":"Thein","sequence":"additional","affiliation":[{"name":"1Sickle Cell Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"2026060911325203000_bib1","doi-asserted-by":"crossref","first-page":"1242815","DOI":"10.3389\/fneur.2023.1242815","article-title":"Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy","volume":"14","author":"Poli","year":"2023","journal-title":"Front Neurol"},{"issue":"9","key":"2026060911325203000_bib2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"2026060911325203000_bib3","doi-asserted-by":"crossref","first-page":"6221","DOI":"10.1038\/s41467-024-50231-1","article-title":"Determinants of transthyretin levels and their association with adverse clinical outcomes among UK Biobank participants","volume":"15","author":"Shetty","year":"2024","journal-title":"Nat Commun"},{"key":"2026060911325203000_bib4","doi-asserted-by":"crossref","first-page":"949401","DOI":"10.3389\/fneur.2022.949401","article-title":"The frequency of V122I transthyretin mutation in a cohort of African American individuals with bilateral carpal tunnel syndrome","volume":"13","author":"Shije","year":"2022","journal-title":"Front Neurol"},{"issue":"21","key":"2026060911325203000_bib5","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jama.2024.4467","article-title":"Cardiovascular burden of the V142I transthyretin variant","volume":"331","author":"Selvaraj","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"2026060911325203000_bib6","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/jamacardio.2024.2190","article-title":"Prevalence, cardiac phenotype, and outcomes of transthyretin variants in the UK Biobank population","volume":"9","author":"Aung","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"9","key":"2026060911325203000_bib7","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jchf.2023.02.003","article-title":"Cardiovascular disease and mortality in Black women carrying the amyloidogenic V122I transthyretin gene variant","volume":"11","author":"Haring","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"7","key":"2026060911325203000_bib8","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in Black Americans","volume":"336","author":"Jacobson","year":"1997","journal-title":"N Engl J Med"},{"issue":"5","key":"2026060911325203000_bib9","doi-asserted-by":"crossref","first-page":"e003356","DOI":"10.1161\/CIRCGEN.121.003356","article-title":"Prevalence and outcomes of p.Val142Ile TTR amyloidosis cardiomyopathy: a systematic review","volume":"14","author":"Chandrashekar","year":"2021","journal-title":"Circ Genom Precis Med"},{"issue":"7","key":"2026060911325203000_bib10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/gim.2016.200","article-title":"Transthyretin V122I (pV142I)\u2217 cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans","volume":"19","author":"Buxbaum","year":"2017","journal-title":"Genet Med"},{"issue":"1","key":"2026060911325203000_bib11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic V122I transthyretin variant in elderly Black Americans","volume":"372","author":"Quarta","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"2026060911325203000_bib12","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2019.17935","article-title":"Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of African or Hispanic\/Latino ancestry","volume":"322","author":"Damrauer","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"2026060911325203000_bib13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ejhf.2776","article-title":"Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy","volume":"25","author":"Porcari","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"2026060911325203000_bib14","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamacardio.2020.6623","article-title":"Association of the V122I transthyretin amyloidosis genetic variant with cardiac structure and function in middle-aged Black adults: Coronary Artery Risk Development in Young Adults (CARDIA) study","volume":"6","author":"Sinha","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"8","key":"2026060911325203000_bib15","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1016\/S2352-3026(23)00118-7","article-title":"Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021","volume":"10","author":"GBD 2021 Sickle Cell Disease Collaborators","year":"2023","journal-title":"Lancet Haematol"},{"key":"2026060911325203000_bib16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-pathmechdis-012418-012838","article-title":"Pathophysiology of sickle cell disease","volume":"14","author":"Sundd","year":"2019","journal-title":"Annu Rev Pathol"},{"key":"2026060911325203000_bib17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1146\/annurev-genom-083117-021320","article-title":"Sickle cell anemia and its phenotypes","volume":"19","author":"Williams","year":"2018","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"6","key":"2026060911325203000_bib18","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2018-10-880575","article-title":"Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis","volume":"133","author":"DeBaun","year":"2019","journal-title":"Blood"},{"issue":"10","key":"2026060911325203000_bib19","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1182\/blood-2016-05-716910","article-title":"Survival in adults with sickle cell disease in a high-income setting","volume":"128","author":"Gardner","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2026060911325203000_bib20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.tcm.2020.02.002","article-title":"Cardiovascular complications of sickle cell disease","volume":"31","author":"Sachdev","year":"2021","journal-title":"Trends Cardiovasc Med"},{"issue":"10037","key":"2026060911325203000_bib21","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/S0140-6736(16)00647-4","article-title":"Cardiovascular complications and risk of death in sickle-cell disease","volume":"387","author":"Gladwin","year":"2016","journal-title":"Lancet"},{"key":"2026060911325203000_bib22","first-page":"11","volume-title":"Sickle Cell Disease","author":"Steinberg MHT","year":"2021","edition":"1st ed"},{"issue":"5","key":"2026060911325203000_bib23","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/bjh.17342","article-title":"A phenotypic risk score for predicting mortality in sickle cell disease","volume":"192","author":"Sachdev","year":"2021","journal-title":"Br J Haematol"},{"issue":"6779","key":"2026060911325203000_bib24","doi-asserted-by":"crossref","first-page":"eadx2678","DOI":"10.1126\/science.adx2678","article-title":"A human pan-disease blood atlas of the circulating proteome","volume":"390","author":"Alvez","year":"2025","journal-title":"Science"},{"key":"2026060911325203000_bib25","author":"Pfeiffer","year":"2017","edition":"1st ed"},{"issue":"14","key":"2026060911325203000_bib26","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/jama.2022.2896","article-title":"Association of transthyretin Val122Ile variant with incident heart failure among Black individuals","volume":"327","author":"Parcha","year":"2022","journal-title":"JAMA"},{"issue":"2","key":"2026060911325203000_bib27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jchf.2021.09.006","article-title":"Transthyretin V142I genetic variant and cardiac remodeling, injury, and heart failure risk in Black adults","volume":"10","author":"Coniglio","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"1","key":"2026060911325203000_bib28","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1182\/asheducation-2017.1.423","article-title":"Cardiovascular complications in patients with sickle cell disease","volume":"2017","author":"Gladwin","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"9","key":"2026060911325203000_bib29","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/ajh.26271","article-title":"Cardiovascular phenotypes predict clinical outcomes in sickle cell disease: an echocardiography-based cluster analysis","volume":"96","author":"d'Humieres","year":"2021","journal-title":"Am J Hematol"},{"issue":"5993","key":"2026060911325203000_bib30","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1193032","article-title":"Association of trypanolytic ApoL1 variants with kidney disease in African Americans","volume":"329","author":"Genovese","year":"2010","journal-title":"Science"},{"key":"2026060911325203000_bib31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-physiol-021119-034345","article-title":"APOL1 and kidney disease: from genetics to biology","volume":"82","author":"Friedman","year":"2020","journal-title":"Annu Rev Physiol"},{"issue":"3","key":"2026060911325203000_bib32","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1365-2141.2011.08832.x","article-title":"MYH9 and APOL1 are both associated with sickle cell disease nephropathy","volume":"155","author":"Ashley-Koch","year":"2011","journal-title":"Br J Haematol"},{"issue":"2","key":"2026060911325203000_bib33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3324\/haematol.2011.050336","article-title":"Association between hemolysis and albuminuria in adults with sickle cell anemia","volume":"97","author":"Day","year":"2012","journal-title":"Haematologica"},{"issue":"3","key":"2026060911325203000_bib34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrneph.2015.8","article-title":"Sickle cell disease: renal manifestations and mechanisms","volume":"11","author":"Nath","year":"2015","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"2026060911325203000_bib35","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2215\/CJN.15161219","article-title":"APOL1 nephropathy: from genetics to clinical applications","volume":"16","author":"Friedman","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2026060911325203000_bib36","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/jcpt.12145","article-title":"Recent progress in the understanding and treatment of transthyretin amyloidosis","volume":"39","author":"Sekijima","year":"2014","journal-title":"J Clin Pharm Ther"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/4000\/2524206\/blooda_adv-2026-019698-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/4000\/2524206\/blooda_adv-2026-019698-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:33:04Z","timestamp":1781019184000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/11\/4000\/567514\/Transthyretin-V122I-variant-and-protein-affect"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,6,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026019698","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,9]]},"published":{"date-parts":[[2026,5,29]]}}}